StockNews.com Begins Coverage on Genocea Biosciences (NASDAQ:GNCA)
StockNews.com Begins Coverage on Genocea Biosciences (NASDAQ:GNCA)
Equities researchers at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report released on Saturday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新闻网的股票研究人员在周六发布的一份报告中开始报道Genocea Biosciences(纳斯达克代码：GNCA-GET Rating)的股票。该公司对这家生物技术公司的股票设定了“卖出”评级。
Genocea Biosciences Stock Performance
Genocea Bioscions股票表现
Shares of GNCA stock opened at $0.01 on Friday. The business's fifty day moving average price is $0.01 and its 200 day moving average price is $0.35. Genocea Biosciences has a 1-year low of $0.01 and a 1-year high of $2.16. The firm has a market capitalization of $657,820.80, a PE ratio of -0.02 and a beta of 1.96. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
上周五，GNCA的股票开盘报0.01美元。该业务的50日移动均线价格为0.01美元，其200日移动均线价格为0.35美元。Genocea Biosciences的一年低点为0.01美元，一年高位为2.16美元。该公司市值为657,820.80美元，市盈率为-0.02，贝塔系数为1.96。该公司的债务权益比为0.24，流动比率为1.35，速动比率为1.35。
Institutional Inflows and Outflows
机构资金流入和流出
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC acquired a new position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. 9.31% of the stock is owned by institutional investors and hedge funds.
一家对冲基金最近购买了Genocea Biosciences股票的新股份。根据Acadian Asset Management LLC在第四季度收购了Genocea Biosciences，Inc.(纳斯达克代码：GNCA-GET Rating)的新股票头寸，该公司在最近提交给美国证券交易委员会的信息中称。该机构投资者购买了这家生物技术公司21,741股股票，价值约25,000美元。9.31%的股票由机构投资者和对冲基金持有。
About Genocea Biosciences
关于Genocea生物科学
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物制药公司，发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
- MarketBeat：回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏，这些股票可能表现优异
- DocuSign是否即将发生重大逆转？
- 石油和天然气股票：投资可再生能源的安全途径
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。